Avoid common mistakes on your manuscript.
Correction to: Neurol Ther (2024) 13:611–624 https://doi.org/10.1007/s40120-024-00591-z
In Fig. 2d of this article the values of HIT-6 at week 12 for CM and HFEM were swapped. The correct values are as follows and the figure should have appeared as shown below.
HIT-6: week 12 HFEM corresponds to − 18.1
HIT-6: week 12 CM corresponds to − 22.5
Fig. 2 d Headache Impact Test-6 (HIT-6) score from baseline to week 48 in patients affected by high-frequency episodic migraine (HFEM, n = 49) or chronic migraine (CM, n = 81)
The original article has been corrected.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Barbanti, P., Egeo, G., Proietti, S. et al. Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study. Neurol Ther (2024). https://doi.org/10.1007/s40120-024-00648-z
Published:
DOI: https://doi.org/10.1007/s40120-024-00648-z